Phase 1 Study of PF-08046033 in Advanced Solid Tumors

This is an early-stage (Phase 1) clinical study testing a new study medicine called PF-08046033. The goal of the study is to understand how safe the medicine is, how well people tolerate it, how it behaves in the body, and whether it shows early signs of helping to treat cancer. The study includes adult participants who have advanced cancers that cannot be removed by surgery or have spread to other parts of the body. These cancers include non-small cell lung cancer, esophageal squamous cell cancer, and melanoma. The study has two parts: In the first part, small groups of participants receiv

Trial Details

NCT ID
NCT07519655
Phase
PHASE1
Sponsor
Pfizer
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • PF-08046033
Locations (sample)
  • Denver, Colorado, United States|39.73915,-104.9847
  • Denver, Colorado, United States|39.73915,-104.9847
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • Rio Piedras, Puerto Rico|18.39745,-66.04989

Key Eligibility Criteria

  • Participants must have histologically-confirmed metastatic or unresectable locally advanced NSCLC, ESCC, or cutaneous melanoma.
  • Participants must have disease that has progressed on or be unable to tolerate standard treatments (Part 1) or 1-2 prior systemic therapies (Part 2).
  • Participants must have measurable disease.
  • Eastern Cooperative Oncology Group (ECOG) performance status is 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →